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REVIEW
Cell-based therapies for the treatment of sports injuries of the upper limb
Kwaku Baryeh a, Vipin Asopa a, Nardeen Kader a, Nick Caplanb, Nicola Maffulli c and Deiary Kader a
aAcademic Surgical Unit, South West London Elective Orthopaedic Centre, Epsom, UK; bFaculty of Health and Life Sciences, Northumbria University, 
Newcastle upon Tyne, UK; cCentre for Sports and Exercise Medicine, Barts and the London School of Medicine and Dentistry, Mile End Hospital, 
Queen Mary University of London, London, UK
ABSTRACT
Introduction: The use of cell-based therapies in the management of sports injuries of the upper limb is 
increasingly popular despite the limited scientific evidence available for their use. We aim to evaluate 
the evidence for the use of cell-based therapies in these injuries and recommend areas for further 
research.
Areas covered: In accordance with a published protocol (PROSPERO; Registration No. 
CRD42020193258), a comprehensive search of the literature was performed using the MEDLINE and 
EMBASE databases from inception to June 2020. All human studies reporting on the clinical, histologi-
cal, or radiological outcomes following the use of cell-based therapies in the management of epicon-
dylitis or rotator cuff pathology were included in this study. This resulted in 22 studies being included in 
this review, all of which underwent risk of bias assessments.
Expert opinion: The evidence for the use of cell-based therapies in upper limb sports injuries is limited 
and generally of low quality. Given the heterogeneity in the cell types used, their harvesting methods 
and cell amounts, future research should be targeted at developing standardization of the reporting of 
these studies and more direct comparative studies looking at the efficacy of the different cell types.
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1. Introduction
Injuries of the upper limb are debilitating to athletes, with 
tendinopathies of the shoulder and elbow being among the 
most prevalent [1]. Rotator cuff pathology represents the most 
common shoulder pathology, for which patients seek medical 
attention [2], and epicondylitis represents a prevalent cause of 
patients presenting with elbow pain [3]. Despite the preva-
lence of these conditions, the success of the currently avail-
able treatment options is variable, with the rate of re-tear 
following rotator cuff repair reported to range from 20% to 
as high as 94% [4,5], and recurrence rates of up to 25% in non- 
operatively treated epicondylitis [6].
One of the reasons for the difficulty in treating these injuries is 
the complex organization of the area of insertion of tendons into 
the bone, the enthesis. The enthesis is comprised of four zones: 
tendon, unmineralized fibrocartilage, mineralized fibrocartilage, 
and bone [7]. Rotator cuff and epicondylar tendinopathy share 
common histological features [8]. Often, following surgical repair, 
fibrovascular scar tissue forms between tendon and bone, result-
ing in a weakened construct, and subsequent failure of repair [9]. 
This inability to restore the normal biology of the tendon has 
meant that, despite technical advances in surgical treatment, 
failure rates are still high. However, cell-based therapies have 
shown promise in their ability to restore the natural biology of 
damaged tendons [10].
Cell-based therapies include a multitude of treatment mod-
alities using cells at various stages of differentiation. Given their 
potential applications in musculoskeletal medicine [11,12], it is 
not surprising that their popularity continues to increase [13]. At 
the heart of these advancements are mesenchymal stem cells 
(MSC) and tenocytes [14,15].
Mesenchymal stem cells are multipotent cells able to differ-
entiate into any type of cell of mesodermal lineage in vitro; these 
include chondrocytes, osteocytes, and adipocytes [16]. However, 
in vivo, this has not yet been demonstrated [17–19]. Tenocytes 
also have some limited potential as a progenitor cell [20]. These 
unique abilities render cell-based preparations a potentially 
invaluable tool in the treatment of musculoskeletal sports inju-
ries, and may offer a quicker return to sport [21–23]. In vivo, the 
therapeutic effects of MSC are likely resulting from their trophic, 
paracrine and immunomodulatory functions as opposed to pro-
liferation and differentiation [24–26]. Much like MSC, tenocytes 
stimulate growth factors and other immunomodulatory cells to 
promote a healing response [27].
The term MSC was coined by Caplan in 1991 [28]. Despite 
their name, MSC are not stem cells. The National Institutes of 
Health (NIH) defined stem cell as a cell from the embryo, fetus, 
or adult that has, under certain conditions, the ability to 
reproduce itself for long periods (long-term self-renewal), 
remain unspecialized or differentiate to specialized cells [29]. 
Neither MSC nor tenocytes have this ability, and so cannot be 
called stem cells. As a result, the International Society for 
Cellular referred to these cells as mesenchymal stromal cells 
[30]. Indeed, Caplan himself advocated a change in 
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nomenclature from MSC to ‘medicinal signaling cells’ to better 
reflect their in vivo secretory function [31]. However, the term 
MSC has persisted, and there are currently several clinicians 
overstating the capabilities of these cell-based therapies, with 
a rapid rise in the number of rogue ‘stem cell’ clinics [32].
The most common sources of MSC are bone marrow and 
adipose tissue [33,34]. They are found infrequently in the bone 
marrow, making up less than 0.01% of mono-nucleated cells 
[16,35,36] or a few hundred cells per milliliter [37]. In contrast, 
adipose tissue contains roughly 400,000 MSC per milliliter of 
lipoaspirate [38]. To increase the concentration of these cells 
further, processing is performed; the concentrate produced is, 
thus, referred to as bone marrow concentrate (BMC) for bone 
marrow or the stromal vascular fraction (SVF) in the case of 
lipoaspirate [39,40]. Given the heterogeneity of the sources of 
MSC, one could be forgiven for failing to see the common link. 
Recent studies have identified the pericyte as the origin of 
most, if not all, MSC [41]. Pericytes are ubiquitous and found in 
all vascularized tissues, and as such, MSC can be isolated from 
all vascularized tissues [25]. This means that, in the event of 
vessel damage, the released pericytes, activated by the injury, 
become MSC engendering a regenerative environment to 
promote healing of the injured tissue [17].
Cell-based therapies for the treatment of sports related 
injuries are being increasingly used given the relative safety 
of their use, quicker return to sport and ability to treat tissues 
that are slow or difficult to heal [42]. Despite their clear 
potential, cell-based therapies have little scientific evidence 
for their use. This review aims to address two central ques-
tions: what the available evidence for the use of cell-based 
therapies in the treatment of rotator cuff and epicondylar 
injuries is, and where should future research be directed.
2. Methods
2.1. Search strategy
This study was performed in line with the Preferred Reporting 
Items for Systematic Review and Meta-Analysis (PRISMA) 
guidelines [43]. It was prospectively registered on the 
International Prospective Register of Systematic Reviews 
(PROSPERO; Registration No. CRD42020193258)
A preliminary search of the literature on regenerative cell 
use in common sports injuries was performed. Several articles 
were found encompassing both lower limb and upper limb 
injuries. A separate review investigating the pathologies asso-
ciated with lower limb injuries was performed [44]. Given the 
difficulties associated with enthesopathies, a decision was 
made to focus on the two most common and difficult to 
treat upper limb enthesopathies, namely, rotator cuff and 
epicondylar injuries.
A sensitive search strategy for multiple databases was 
devised by one author (NK). A comprehensive search of the 
literature was performed using the MEDLINE and EMBASE 
databases from inception to June 2020. Article titles were 
searched for the following terms, limited to humans, as well 
as their corresponding or related MeSH terms: ‘mesenchymal 
stem cell’ OR ‘stem cell’ OR ‘stromal vascular fraction’ OR ‘bone 
marrow’ OR ‘tenocyte’ in two separate searches where they 
were combined with the following:
Search 1, MSC use in rotator cuff pathology, all fields lim-
ited to ‘Human’:
AND ‘rotator cuff’ [KEYWORD] OR ‘rotator cuff injury’ 
[KEYWORD] OR related MeSH terms.
Search 2, MSC use in epicondylar tendinopathy, all fields 
limited to ‘Human’:
AND ‘epicondylitis’ [KEYWORD] OR ‘tennis elbow’ 
[KEYWORD] OR related MeSH terms.
To search the gray literature, each trial registry was 
searched for ‘mesenchymal stem cell’ and ‘regenerative cell’ 
on 06.06.2020 using the following databases to capture any 
results from finished trials with unpublished results: CENTRAL 
trials registry of the Cochrane Collaboration, WHO 
International Clinical Trials Registry Platform (ICTRP), EU 
Clinical Trials Register and ClinicalTrials.gov.
The references of the included studies were also searched 
manually for further relevant studies.
2.2. Eligibility criteria
Studies were included if the following inclusion criteria (PICOS) 
were met:
Population. Male and female humans who have either 
epicondylitis or rotator cuff pathology.
Interventions. The use of cell-based therapies includes 
mesenchymal stem cells, tenocytes, tenocyte-like cells, and 
any processed or concentrated cell preparations thought to 
contain mesenchymal stem cells, such as stromal vascular 
fraction and bone marrow concentrate.
Control. Patients with epicondylitis or rotator cuff pathol-
ogy treated without the use of cell-based therapies.
Outcomes. Studies had to contain clinical outcomes such as 
patient reported outcome measures (PROMs), histological ana-
lysis of tendon tissue pre- and post-intervention or imaging 
outcomes such as an evaluation of tear size or tendon healing 
following the use of cell-based therapies.
Study designs. Randomized controlled trials (RCT), con-
trolled clinical trials (CT), retrospective studies, non- 
randomized studies, cohort studies, case series, and case 
reports.
2.3. Data collection
Titles and abstracts were screened by two authors (NK and KB) 
for relevance. Following this, selection criteria were applied 
independently by two authors (NK and KB). If unclear from the 
review of the title and abstract whether a study was appro-
priate for inclusion, full texts were examined. Consensus was 
used to resolve any disagreements between reviewers, refer-
ring to a third, senior reviewer (VA) if consensus was not 
reached.
2.4. Data extraction
The following data were extracted: patient demographics (age, 
sex), nature of injury, intervention performed, biologic used 
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and the source, cell count of biologic, functional outcomes 
(PROMs), radiological outcomes and length of follow up.
For all studies containing data presented as means with 
standard deviations or standard errors, values of all relevant 
outcome measures for pre- and post-intervention were 
extracted in order to calculate the effect sizes.
2.5. Quality assessment of included studies
A risk of bias assessment was completed using the Cochrane 
Risk of Bias 2 (RoB2) tool for RCTs. This tool provides an 
algorithm by which an overall risk of bias judgment is reached 
per each study. Five domains were evaluated for risk of bias 
(the randomization procedure, deviations from the intended 
interventions, missing outcome data, measurement of the 
outcome, and selection of the reported result) by two authors 
(KB and NK) independently. Each domain was labeled as either 
high risk of bias, low risk of bias, or some concerns. If a study 
had all five domains as low risk, the overall risk of bias would 
be low. However, if any of the five domains were labeled high 
risk or some concern, their overall risk of bias would also be 
high risk or some concern, respectively. Any disagreements 
that arose were resolved by a third author (VA).
Case series, case-control studies and cohort studies were 
assessed using the Agency for healthcare research and quality 
(AHRQ) tool [45]. Using this tool cohort, studies had 
a maximum of 13 stars, case-control studies had a maximum 
of 11 stars, and case series had a maximum of 9 stars, where 
the greater the number of stars, the lower the risk of bias.
2.6. Data analysis
To provide an overall summary of the data extracted, for all 
studies containing data presented as means with standard 
deviations or standard errors, effect sizes were calculated for 
available outcomes. For RCTs, the mean difference between 
pre- and post-surgery was calculated for each outcome in 
both the intervention and control groups. Effect sizes were 
then calculated between the mean differences in the interven-
tion and control groups. For non-RCTs, effect sizes were calcu-
lated from the pre- and post-intervention data. Given the 
typically small sample size in each study, effect sizes were 
bias corrected using the Hedge’s G method [46]. All calculated 
effect sizes were defined as small (0.2), medium (0.5), large 
(0.8), or very large (1.3) [47], and were presented in effect size 
plots with 95% confidence interval error bars.
Outcomes were grouped according to the injury they 
reflect: RC or epicondylitis. Injury patterns were further divided 
into RCT and non-RCT studies. Given the heterogeneity of the 
study protocols, a full meta-analysis was not possible.
3. Results
The primary search yielded 337 results (see PRISMA flowchart – 
Figure 1).
After reviewing full texts, both authors (NK, KB) agreed that 
16 studies were eligible for inclusion. After searching through 
the references of eligible studies and all relevant review arti-
cles manually, five further cited studies were found to be 
eligible for inclusion. One additional study with available 
data was found by searching the gray literature.
Of the 22 studies that met the inclusion criteria, 16 were 
relating to rotator cuff pathology and 6 to epicondylitis. 
A summary of the main study characteristics can be found in 
Table 1.
3.1. Risk of bias assessment
The three included RCTs were assessed for risk of bias using 
the Cochrane RoB2 tool with all three displaying some con-
cerns for bias (see Table 2 and Figure 2[48]). Sixteen studies 
were assessed using the AHRQ tool (see Table 3). The seven 
case series [49–55] had risk of bias assessment between 4 and 
6 out of nine stars. The two case-control studies [56,57] had 
risk of bias assessments between 6 and 9 out of 11 stars. The 
seven cohort studies [58–64] had risk of bias assessments 
between 6 and 10 out of 13 stars. The three case reports 
[27,65,66] were assumed to be at a high risk of bias, and 
thus not assessed further.
3.2. Shoulder: Rotator Cuff Injury
Sixteen studies involving the use of cell-based therapies in 
rotator cuff disease were found. Seven studies assessed aug-
mentation of RC repair surgery, and nine evaluated the use of 
intra-articular, or intra-tendinous, injections.
3.2.1. Bone Marrow Concentrate
Three studies investigated the use of BMC alone. Two studies 
[55,56] involved BMC augmented surgical repair of the RC and 
demonstrated maintained tendon integrity on MRI in 87% of 
patients at 10 years [56] and 100% of patients at 12 months 
[55]. The remaining study [62] demonstrated improved pain 
and function scores following BMC injection.
Ellera Gomes et al. [55] reported on 14 patients with com-
plete RC tears. All patients underwent an augmented mini- 
open RC repair by a single surgeon and BMC was injected into 
the tendon and the bony footprint. This was followed by 
4 weeks immobilization in a sling and physiotherapy there-
after. The UCLA shoulder score improved from 12 ± 3 preo-
peratively to 31 ± 3.2 at a minimum of 12 months follow up. 
Magnetic resonance imaging follow-up was available in all 
patients at 12 months and all 14 patients demonstrated ten-
don integrity.
Hernigou et al. [56] reported on 45 patients with supraspi-
natus tears matched for tear size and location, shoulder dom-
inance, sex, and age with an equivalent group. All procedures 
were undertaken using arthroscopic techniques. In the experi-
mental group, BMC were injected at the tendon bone junction 
and the bony footprint. In both groups, the first week post- 
operatively involved an arm sling and passive forward flexion. 
Active range of motion exercises were commenced at 6 weeks, 
and active resistance exercises at 8 weeks. Light daily activities 
were allowed from 2 months, and heavy manual work or 
sporting activities allowed after 6 months. At the 10-year 
follow-up MRI, 39 of 45 patients (87%) in the experimental 
group had intact RC compared to 20 of 45 patients (44%) in 
the control group (p < 0.05).
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Darrow et al. [62] retrospectively evaluated the use of 
either BMC or whole bone marrow, injected into the joints 
and tendons of 18 subjects with RC tears. Participants were 
advised to perform daily shoulder stretches as part of their 
rehabilitation. They reported improved functional outcomes 
and pain scores for both groups but did not provide separate 
data or information on the size of tears and specific site of 
injection.
3.2.2. Bone Marrow Concentrate (BMC) and Adjunctive 
therapies
Five studies reported on the use of BMC and other therapies. 
One study [64] reported on the use of BMC and adjunctive 
therapies in revision RC surgery and found functional scores 
that trended toward improvement, although for the most part 
these were not significant. Four studies [57–59,67] reported on 
the results of BMC and adjunctive therapies injected into RC 
tendon. All four studies reported improvements in functional 
scores following the injection of BMC and adjunctive thera-
pies, two of which were compared with a control group 
[57,67]. No significant improvement in tear size was demon-
strated when compared to baseline [67] or control groups [57].
Muench et al. [64] reported on the use of a biologically 
augmented patch saturated with a BMC/Platelet Rich Plasma 
(PRP) mix in 22 patients who required revision rotator cuff 
surgery. Patients were placed in a 30 degree abduction sling 
for at least 6 weeks. From day 28 postoperatively, patients 
were allowed 60 degrees of active assisted external rotation, 
30 degrees of abduction and forward flexion from 30 to 180 
degrees during physical therapy. Subsequently, patients were 
allowed to start active assisted range of motion in external 
rotation and forward flexion without limitations up to 
12 weeks postoperatively. This was followed by RC strength-
ening until 18 weeks. The Simple Shoulder Test (SST) scores 
improved from 2.6 ± 3.0 pre-operatively to 5.2 ± 4.2 post- 
operatively (p < 0.05). The American Shoulder and Elbow 
Surgeon (ASES) score increased from 40.2 ± 21.6 pre- 
operatively to 53.9 ± 31.4 post- 
operatively; however, statistical significance was not reached. 
The Visual Analogue Scale (VAS) pain scores decreased from 
5.6 ± 2.5 pre-operatively to 4.2 ± 3.4, again this did not reach 
statistical significance.
Centeno et al. [58] reported on two distinct groups of 
patients, one with osteoarthritis and one with RC disorders. 
Improvements in the functional scores of patients who 
received intra-articular/intra-tendinous injections of 
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Figure 1. PRISMA 2009 Flow Diagram.
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a combination of BMC, PRP and Plasma Lysate (PL) were 
reported. No details regarding rehabilitation were available. 
The Disabilities of the Arm, Shoulder and Hand score (DASH) 
improved from 36.1 pre-treatment to 17.1 post-treatment at 
an average follow-up of 7.1 months (p < 0.001). Similarly, the 
numeric pain scale (NPS) improved from 4.3 pre-treatment to 
2.4 post-treatment at a mean follow-up of 8.3 months 
(p < 0.001). However, the results were not separated between 
the RC group and the osteoarthritis group. When the two 
groups were compared, uni and multivariate analysis showed 
no differences in outcomes.
Kim et al. [57,59] published two studies reporting on 12 
patients who had sub-acute partial rotator cuff tears. The 
initial study reported on 12 patients who had a BMC-PRP 
mixture injected into the site of their tear. In the second 
study, the patients from the initial group were compared to 
a control group who received physiotherapy alone. The 
experimental group had no rehabilitation, while the control 
group were shown RC exercises to perform for 3 months. After 
3 months, the treatment group showed greater functional 
outcome improvements compared to the control group (VAS 
1.9 ± 0.7 and 3.7 ± 1.8, respectively (p < 0.05) and ASES 
74.1 ± 8.5 and 62.2 ± 12.2, respectively (p < 0.05)). There 
were no significant changes in tear size between the two 
groups.
Centeno et al. [67] performed a prospective RCT crossover 
trial with 14 patients in the treatment group receiving a BMC 
injection and a second group receiving exercise therapy. 
Patients were instructed to limit lifting and pushing and to 
perform passive range of motion exercises thrice daily up 
to day three post-procedure. From day three to week four, 
patients were encouraged to continue thrice daily range of 
motion exercises with the addition of pendulum, pulley exer-
cises, and shoulder girdle strengthening exercises. From weeks 
five to 11, patients were advised to start resistance training, 
and with no restrictions after week 12. They found significant 
improvements in the Disabilities of the Arm, Shoulder and 
Hand (DASH) Score, Numerical Pain Scale and Single 
Assessment Numeric Evaluation (SANE) at all time points 
prior to crossover in favor of the BMC-only group. At 
24 months however there were no statistically significant 
differences in these variables between the BMC-only group 
and the crossover group (exercise therapy with the opportu-
nity to cross over at 3 months). Magnetic resonance imaging 
assessment of tears, by three blinded assessors, showed 
a mean decrease in size of 26% in the BMC group, which 
was not statistically significant.
3.2.3. Mesenchymal Stem Cells
Four studies evaluated the use of MSC. Three [60,61,63] stu-
dies reported on the injection of MSC. Functional scores 
increased in all studies, however significance was limited to 
a high dose MSC [61,63] and was not reached compared to 
a control group of arthroscopic repair alone [60]. There was 
also a significant decrease in re-tears in the MSC-treated group 
compared to the control group [60]. In the remaining study 
[68], MSCs were used to augment RC repair and, while func-
tional scores increased in the treatment group, so too did the 
re-rupture rate.
Kim et al. [60] reported on 35 patients treated with adi-
pose-derived MSC/fibrin glue injection compared with 
a control group of 35 patients undergoing surgical repair 
alone. Passive exercises were permitted from the day after 
surgery, while active exercises were not permitted until at 
least week six. Active assisted exercises were initiated 6 
weeks after surgery alongside muscle-strengthening exercises. 
Manual labor or recreational activities were delayed for 6 
months. The Constant score in the injection group improved 
from 65.2 ± 14.6 pre-operatively to 78.3 ± 14.9 postoperatively 
(P < 0.001). The UCLA score increased from 26.5 ± 5.2 pre- 
operatively to 29.8 ± 5.1 post-operatively. This improvement 
did not reach statistical significance. There were no statistically 
significant differences between the UCLA scores and Constant 
score between both groups during the final follow-up. The 
VAS scores at rest and during motion also saw statistically 
significant improvements in both groups, with no difference 
between the groups. The structural outcomes of the injection 
group, as assessed by MRI at a mean of 13.9 months (12–-
21 months), showed 30 tears with complete healing, with 
a statistically significant reduction in the number of re-tears 
(5 vs 10 p < 0.001). There was a statistically significant reduc-
tion in re-tears in patients who had full thickness tears (3 vs 9 
p < 0.001).
Lamas et al. [68] reported on eight patients using 
a xenogeneic scaffold augmented with bone marrow derived 
from cultured MSC compared to a control group of five 
patients who received the scaffold alone. Post-operatively, 
patients were placed in an abduction sling for a non- 
Table 2. Risk of bias domains.
Figure 2. Assessment of risk of bias.
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specified duration. The trial was stopped early because of 
a high complication rate. Of those who completed the study, 
five patients (62.5%) sustained a re-rupture in the MSC group 
compared to three patients (60%) in the control group. The 
Constant score improved from a mean of 44.5 (30–63) pre- 
operatively to 72 (43–87) post-operatively and the VAS 
improved from 8.1 (7–9) pre-operatively to 2.9 (1–8) post-
operatively in the MSC group.
Jo et al. [61] divided 19 participants receiving an intra- 
tendinous injection of cultured adipose derived MSCs with 
saline alone into three dosage groups: low, medium and 
high. Post-injection, patients were immobilized for four weeks
in an abduction brace. Shrugging, protraction, and retrac-
tion of shoulder girdles; intermittent exercise of the elbow,
wrist, and hand; and external rotation of the arm to neutral 
with the brace were encouraged as tolerated. Gradual wean-
ing from the abduction brace at 4 weeks with passive and 
active assisted range of motion exercises was commenced and 
strengthening exercises thereafter. The 2-year follow-up 
results were published separately [63]: eight bursal-side 
defects in the high-dose group had a 100% improvement in 
the defect size at 2 years. There was no statistically significant 
improvement in the four articular-side defects in the high- 
dose group nor any of the bursal-side, articular-side or intra- 
tendinous defect sizes in the medium and low-dose groups. 
Functional scores improved in all groups during the final 
follow-up, but these were mostly statistically significant in 
the high-dose group only.
3.2.4. Mesenchymal Stem Cells and adjunctive therapies
A single study evaluated the use of MSC in conjunction with 
other therapies.
Protzman et al. [65] reported the findings of a case of 
recurrent RC tears where a dermal allograft combined with 
MSCs and PRP was used for surgical repair. The post-operative 
rehabilitation regime was not described. A biopsy taken 
8 months post-operatively showed that the graft had become 
fully incorporated and had undergone tissue remodeling.
3.2.5. Tenocytes
The use of tenocytes was reported in two studies. Both studies 
[27,51] report improved tear size following the injection of 
tenocytes.
Wang et al. [66] theorized that the use of tenocyte- 
containing preparations may promote healing ‘through 
replenishing the depleted tenocyte population seen in end- 
stage tendinopathy.’ They reported a single patient in whom 
autologous tenocytes were harvested from the patellar tendon 
and injected into a partial thickness tear. Following injection, 
the patient was rested from all training for 4 weeks. This was 
followed by light training and at 12 weeks the patient was 
allowed to return to full training. Two independent radiolo-
gists reported that the partial thickness supraspinatus tear was 
no longer detectable on MRI scan at 10 months post proce-
dure. However, tendinopathy (as defined by tendon thicken-
ing with persistent focal signal increase) persisted at 10-month 
follow-up.
Schwab et al. [27] reported a patient in whom the subsca-
pularis tendon was injected with tenocytes obtained from 
autologous palmaris longus tendon. Post procedure, there 
was a period of 3 days of complete rest. This was followed 
by modified training in the pool at two and a half weeks, and 
full training over three to 4 weeks. Three blinded radiologists 
reported improvements in both tear size (judged by Walton 
criteria [69]) and tendinopathy.
3.2.6. Stromal Vascular Fraction
Only one study reported the use of SVF.
Hurd et al. [70] used adipose tissue from the abdomen, 
flank or inner thigh to obtain SVF for injection into the ten-
dons of 12 patients. A control group of six patients received 
a corticosteroid injection into the subacromial space. Patients 
were advised to avoid overhead activities for the first 2 days, 
and continue with any home treatment program already insti-
gated. No further specific restrictions were placed. The 
American Shoulder and Elbow Surgeons scores improved 
from a baseline of 58.7 ± 5.8 to 89.4 ± 4.9 at 52 weeks post 
Table 3. Risk of Bias assessments using AHRQ tool.
Author Selection Bias Performance Bias Attrition Bias Detection Bias Reporting Bias Study type
Moon 2008 * * * ** * Case series
Connell 2009 * * ** * Case series
Ellera Gomes 2011 * * ** * Case series
Wang 2013 * * ** * Case series
Hernigou 2014 ** ** * *** * Case control
Singh 2014 * * * * Case series
Centeno 2015 ** * *** * Cohort Study
Lee 2015 * * * ** * Case series
Wang 2015 * * ** * Case series
Kim SJ 2017 *** * * **** * Cohort Study
Kim YS 2017 **** * * *** * Cohort Study
Jo 2018 ** * * *** * Cohort Study
Kim SJ 2018 * * *** * Case control
Darrow 2019 *** * * * Cohort Study
Jo 2020 ** * * *** * Cohort Study
Muench 2020 *** * *** * Cohort Study
Cohort studies – maximum of 13 stars 
Case-control studies – maximum of 11 stars 
Case series – Maximum of 9 stars 
EXPERT OPINION ON BIOLOGICAL THERAPY 7
treatment in the SVF group compared to the steroid group, 
which changed from 50.6 ± 6.7 at baseline to 68.4 ± 4.4at 
52 weeks post treatment (p < 0.05). In the Short Form Survey 
36 (SF-36), VAS and MRI appearances showed no statistically 
significant difference between the groups.
3.2.7. Clinical outcomes
The main clinical outcome scores used were the UCLA 
shoulder score, VAS pain score, ASES score, and Constant 
score. The effect sizes are represented in Figures 3 and 
Figures 4 for relevant studies excluding case reports. Five 
studies [57,59,60,68,70] reported on both pre- and post- 
intervention VAS scores. The average pre-intervention VAS 
was 4.8. This improved to 1.8 at a mean follow up of 
11.7 months (3–28.3 months). Four studies [57,59,64,70] 
reported on the ASES score with an average score pre- 
intervention of 44.4. This improved post-intervention to an 
average of 72.3 at a mean follow-up of 12 months (3–-
30 months). Two studies reported on the UCLA shoulder 
score [55,60] and Constant score [60,68], respectively. The 
SHOULDER - RCT
-2.00 -1.00 0.00 1.00 2.00
Effect size (d)
VAS
Kim SJ et al (2018) at 3 weeks
Kim SJ et al (2018) at 3 months
Lamas et al (2019) at 12 months
Hurd et al (2020) at 24 weeks
Hurd et al (2020) at 52 weeks
ASES
Kim SJ et al (2018) at 3 weeks
Kim SJ et al (2018) at 3 months
Hurd et al (2020) at 24 weeks
Hurd et al (2020) at 52 weeks
Constant
Lamas et al (2019) at 12 months
SF-36
Hurd et al (2020) at 24 weeks
Hurd et al (2020) at 52 weeks
Tear Size
Hurd et al (2020) at 24 weeks
Hurd et al (2020) at 52 weeks
favours control favours intervention
Figure 3. Hedges d effect sizes are shown for the pre-post mean difference in each outcome between intervention and control groups for randomized controlled 
trials of the shoulder. 95% confidence intervals are shown.
SHOULDER
-3.00 0.00 3.00 6.00
Effect size (d)
VAS
Kim SJ et al (2017)
ASES
Kim SJ et al (2017)
Muench et al (2020)
UCLA
Ellera Gomes et al (2011)
SST
Muench et al (2020)
Figure 4. Hedges d effect sizes are shown for the pre-post mean difference in each outcome between intervention and control groups for non-randomized 
controlled trials of the shoulder. 95% confidence intervals are shown.
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mean UCLA score pre-intervention was 19.3. This increased 
post-intervention to 30.4 at a mean follow up of 20.2 months 
(12–28.3 months). The Constant score was a mean of 54.9 pre- 
intervention increase to 75.2 post-intervention at a mean of 
20.2 months (12–28.3 months).
3.2.8. Imaging outcomes
Most of the studies reporting imaging outcomes used MRI as 
their imaging modality of choice. Five studies [57,59,61,67,70] 
reported a decrease in tear size at follow-up (two using ultra-
sound and three using MRI). Four studies [27,60,63,66] 
reported healing in 85.7% to 100% of patients. Two studies 
reported on tendon integrity, with Ellera-Gomes et al. [55] 
reporting integrity in 100% of patients at 12 months and 
Heringou et al. [56] reporting integrity in 87% of patients at 
10-year follow-up.
3.2.9. Complications
Among the complications detailed in the studies, Heringou 
et al. [56] report 6 re-tears between 2 and 4 years. The RCT by 
Lamas et al. [68] was stopped early because of a high compli-
cation rate. In the treatment group, three patients developed 
lesions requiring further surgery. Additionally, the re-tear rate 
was 62.5% in the treatment group, another factor which has-
tened the cessation of the trial. Five patients required revision 
procedures at an average of 1.9 years in the study by Muench 
et al. [64]. Additionally, one patient required excision of painful 
suture material and one patient sustained a deep infection.
3.3. Elbow: Epicondylitis
Six studies concerning the use of cell-based therapies for 
epicondylitis were identified. One involved augmenting surgi-
cal treatment, and theremaining reported results following 
intra-tendinous injections of cell-based preparations into the 
lateral epicondyle.
3.3.1. Bone Marrow Concentrate
Two studies reported on the use of BMC. Both studies report 
improved functional scores following surgical debridement 
[49] or in isolation [52].
Moon et al. [49] investigated the use of autologous BMC 
injections in 26 elbows with epicondylitis (24 patients). The 
patients received a dose of BMCs with bupivacaine immedi-
ately following arthroscopic debridement of degenerative tis-
sue within the common extensor origin. The elbow was 
immobilized in a splint for 2 days, active resistance exercises 
started at 6 weeks postoperatively, and more vigorous exer-
cise allowed after two to 3 months. At 6-month follow-up, 
patients had significant improvements in VAS (7 at baseline 
improving to 1.7) and Mayo Elbow Performance Score (MEPS) 
(52 ± 7.6 at baseline improving to 89 ± 7.9, p < 0.001).
Singh et al. [52] examined the use of BMC injection without 
operative treatment in 26 patients with lateral epicondylitis. 
Post-injection, patients were advised to rest and modify their 
activities. Patient-rated Tennis Elbow Evaluation (PRTEE) scores 
improved from 72.8 ± 7.0 at baseline to 14.86 ± 3.5 at 
3 months (p < 0.0001).
3.3.2. Mesenchymal Stem Cells
One study reported the use of MSC.
Lee et al. [53] investigated injection of allogenic adipose- 
derived cultured MSCs and fibrin glue into the common exten-
sor origin. Twelve participants were split into two groups, 
a low dose group and a high dose group. No specific rehabi-
litation was instigated post injection. The VAS improved from 
a baseline of 66.8 ± 14.5 to 14.8 ± 13.1 at 1 year. Similarly, the 
MEPS improved from a baseline of 64 ± 13.5 to 90.6 ± 5.8 at 
52 weeks. The appearances of tendinous defect on ultrasound 
were also found to have significantly decreased at 52 weeks.
3.3.3. Tenocytes
Three studies reported on the use of tenocytes. All studies 
[50,51,54] demonstrated improved functional scores and 
appearances on imaging following injection of tenocytes.
Wang et al. reported two studies [51,54], the first of which 
included 16 patients injected with patellar tendon-derived 
tenocytes. Patients were advised to rest for 2 days post injec-
tion and then perform only light activities for 4 weeks. 
Additionally, advice regarding four times daily forearm exten-
sor muscle stretches was given. Visual Analogue Scale scores 
improved from 5.9 ± 2.2 at baseline to 0.8 (no standard 
deviation provided) at 12 months. The QuickDASH score 
improved from 45.88 ± 15.2 at baseline to 2.88 ± 0.7 at final 
follow-up (P < 0.001). The MRI appearances of the tendon 
were also significantly improved at 12 months. In the second 
study, the same cohort was followed up to 4.5 years. The 
QuickDASH was 6.61 ± 1.9 at final follow up and VAS was 
1.21 ± 0.3 at final follow up.
Connell et al. [50] performed a similar study using tenocyte- 
like cells derived from skin fibroblasts. In this study, cells were 
injected into the lateral epicondyle of 12 patients. Patients 
were advised to limit the use of the injected arm for 
24 hours after which normal activity could resume bar heavy 
lifting. The PRTEE score improved from a baseline of 78 (71–-
88) to a median of 12 (0–25) at 6 months (p < 0.05). 
Assessment of tendons using ultrasonography at 6 months 
showed improvement in appearance (p < 0.05).
3.3.4. Clinical outcomes
The PRTEE, VAS and MEPS were the most commonly used 
functional scores. The effect sizes are represented in Figure 5 
for relevant studies excluding case reports. Three studies 
[49,53,71] reported on the VAS; at baseline, the mean VAS 
was 6.5 ± 0.5, improving to 1.5 ± 0.2 at an average 24 months 
(6–54.1 months) follow-up. Two studies [49,53] reported on 
the PRTEE score. At baseline, the mean score was 75.4 ± 2.6, 
which improved to 13.4 ± 1.4 at an average of 4.5 months 
(3–6 months) follow up. Two studies [49,53] reported on the 
MEPS, with a baseline of 58 improving to 89.8 at a mean 
follow-up of 9 months (6–12 months).
3.3.5. Imaging outcomes
Four studies reported on imaging outcomes post intervention. 
Two studies [50,53] reported improved defect size and appear-
ances tending toward normality at 6 months and 12 months, 
respectively. Two studies from Wang et al. [51,71] reported on 
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the MRI appearance of the tendon. Both showed improved 
appearances at 12 months, and these improvements were 
maintained at 5 years.
3.3.6. Complications
Of the studies reported, there was only one reported complica-
tion. In the pilot study by Wang et al. [51], one patient exhibited 
worsening of the appearances of the tear post intervention. The 
deterioration resulted in the need for surgical intervention. No 
further complications were reported in any of the studies.
4. Conclusion
Within the limitations of this study, tenocytes have shown the 
most promise in the management of epicondylar tendinopa-
thy. In the studies that used tenocytes, both clinical and 
imaging scores were improved, with imaging improvements 
maintained at up to 5-year follow-up. In the management of 
rotator cuff pathology, BMC showed the most promising 
results when used in isolation or as an adjunct to surgical 
repair. The studies using BMC evidenced improvements in 
functional scores and fewer complications.
In the non-randomized studies, the magnitude of the effect 
of intervention on clinical scores was mostly large, suggesting 
that patient scores are likely to show meaningful improve-
ments following treatment with cell-based therapies. 
However, in the RCTs, the effect magnitude of cell-based 
therapies was only small to medium. This highlights the 
need for further high-quality randomized studies to establish 
whether the use of cell-based therapies truly results in 
improved patient outcomes.
Whilst there are many promising findings reported in the 
included studies, a lack of standardization in methods, culture 
and cell type make firm conclusions difficult to draw. We 
suggest that future studies should focus on establishing 
techniques to reliably identify cell type and number. This 
would lay the foundations for greater comparability of studies, 
and enable direct comparison of outcome measures. It is also 
imperative that the outcomes measured focus on patient pain, 
function and quality of life. To this end, we suggest that 
PROMs should be the primary outcome measure for future 
studies. Whilst imaging evidence of tendon integrity is a useful 
metric of the regenerative abilities of cell-based therapies, if 
this is not accompanied by improvements in a patient’s func-
tion, pain or quality of life, the usefulness of these therapies as 
a suitable treatment would understandably be questioned.
5. Expert Opinion
Twenty-two studies were included in this systematic review, of 
which only three were of level 1 evidence [72]. Three of the 
studies were RCTs, all of which pertained to the treatment of 
rotator cuff injuries. There were mixed results with regard to 
clinical outcomes, with some showing no significant difference 
between treatment and control groups. However, most func-
tional scores were significantly better in the treatment groups 
compared to the control group. None of the studies reported 
serious adverse effects as a result of the cell-based treatment. 
However, Lamas et al. [68] terminated their study early due to 
a number of complications in both treatment and control 
groups which they attributed to the scaffold used.
It was not possible to conduct a meta-analysis of the avail-
able data in any of the sections due to the heterogeneity 
between studies. Studies varied greatly in the type of cell- 
based therapy used, in their functional and imaging outcomes 
and their intervals of measurement/follow up (Table 1). The 
wide variety in the reporting of methods and in the cell 
amounts make replication and standardization of studies diffi-
cult to achieve [73]. However, assessment of effect sizes was 
possible (Figures 3,Figures 4,Figures 5). In the three RCTs 
ELBOW
-16.00 -11.00 -6.00 -1.00 4.00
Effect size (d)
VAS
Moon et al (2008)
Lee et al (2015)
Wang et al (2013)
Wang et al (2015)
MEPS
Moon et al (2008)
Lee et al (2015)
PRTEE
Singh et al (2014)
QuickDASH
Wang et al (2013)
Wang et al (2015)
Figure 5. Hedges d effect sizes are shown for the pre-post mean difference in each outcome between intervention and control groups for non-randomized 
controlled trials of the elbow. 95% confidence intervals are shown.
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[57,68,70] included in this study, with the exception of VAS 
score in the study by Lamas et al. [68], the effect sizes favored 
the intervention group. However, with the exception of the 
ASES score in Kim et al. [57] at 3 months, which showed 
a large effect, the remaining studies showed at best 
a medium effect. For these studies, the confidence intervals 
suggest that, while the majority of patients might see 
a favorable response following surgery, there will also be 
a proportion of patients who do not respond as well, or 
indeed, at all (Figure 3).
In the non-randomized studies of rotator cuff injuries, UCLA 
and VAS scores showed large effect sizes, with the confidence 
intervals indicating all patients could expect to experience 
improvement as a result of intervention. However, while Kim 
et al. [59] demonstrated a large effect for the ASES score, 
Muench et al. [64] demonstrated only a small effect. 
Considering both these studies, the data would suggest that 
the majority of patients would experience a meaningful 
improvement in this outcome following intervention, but 
some may not respond so well. In the non-randomized studies 
of epicondylitis, large effect sizes were demonstrated for all 
clinical scores, with confidence intervals suggesting that all 
patients should achieve a meaningful response to intervention 
(Figure 5). This would indicate that cell-based therapies used 
for the management of epicondylitis would result in improve-
ment in clinical scores for all patients. Whilst these results are 
promising, given the lack of randomization, they should be 
interpreted with a degree of caution.
The use of effect sizes in this study has highlighted the 
issue of responders and non-responders to treatments. This 
issue in any therapy, not just a biological therapy, is very much 
to the forefront in musculoskeletal medicine [74–85], and in 
these days of personalized medicine, this is an issue which 
needs to be taken into account. However, to our knowledge, 
this approach, though desirable and scientifically valid, has not 
been taken when planning investigations in this field. It is 
extremely likely that, although it would make sense to stratify 
patients according to their intrinsic capability and propensity 
to respond to a given therapeutic intervention, the practical-
ities and costs of such an approach would be prohibitive.
Serious complications related to the use of cell-based 
therapies are rare [40], with the majority of complications 
reported being limited to pain related to route of administra-
tion [86]. Among the studies included in this review, there was 
a low rate of complications, with none being directly attribu-
ted to the use of cell-based therapies.
The standardization of cell-based therapies would enable 
greater comparability of studies, and also allow the utilization 
of demonstrably successful techniques to improve patient care. 
Unfortunately, given the complexity in the heterogeneity of the 
cells and the variability in their procurement, this is unlikely to 
happen in the near future [87]. The American Academy of 
Orthopedic Surgeons (AAOS) have suggested methods for 
achieving greater standardization which include everything 
from nomenclature to the source and preparation of MSC 
[73,88]. However, until a global consensus is reached, it is unlikely 
that advances in the field will be reproducible on a large scale. 
One recently developed reporting tool, which reached 
a consensus using a modified Delphi method, is the DOSES 
tool [89]. This tool implores the researcher to report the Donor, 
Origin tissue, Separation method, Exhibited cell characteristics, 
and Site of delivery of the cell-based therapy used. By utilizing 
reporting tools like DOSES, it is hoped that the transparency and 
standardization of cell-based therapies can be achieved. This 
would allow for a greater understanding of the preparations 
and, once their efficacy was established, allow greater reprodu-
cibility in their clinical applications.
The potential for cell-based therapies in the management of 
sports injuries is limitless. In the future, in select cases, cell-based 
therapies may eliminate the need for the surgical management of 
common sports injuries, thus removing an element of risk. With 
a move toward standardization of reporting and greater regula-
tion of cell-based therapies, it is likely that they will become more 
widely available and, with this, the ability to conduct high quality 
and more readily reproducible studies will also increase.
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